Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types

by Jeffrey S Ross, Richard S P Huang, Jake G Maule, Lani K Clinton, Ryon P Graf, Jinpeng Xiao, Geoffrey R Oxnard
Published 2022-10-01

Detection of EGFR mutations in non-small cell lung cancer by droplet digital PCR.

by Drew F K Williamson, Sean R N Marris, Vanesa Rojas-Rudilla, Jacqueline L Bruce, Cloud P Paweletz, Geoffrey R Oxnard, Lynette M Sholl, Fei Dong
Published 2022-01-01

Detection of EGFR mutations in non-small cell lung cancer by droplet digital PCR

by Drew F. K. Williamson, Sean R. N. Marris, Vanesa Rojas-Rudilla, Jacqueline L. Bruce, Cloud P. Paweletz, Geoffrey R. Oxnard, Lynette M. Sholl, Fei Dong
Published 2022-01-01

Potential pathogenic germline variant reporting from tumor comprehensive genomic profiling complements classic approaches to germline testing

by Nadine Tung, Kali Chatham Dougherty, Emily Stern Gatof, Kim DeLeonardis, Lauren Hogan, Hanna Tukachinsky, Erica Gornstein, Geoffrey R. Oxnard, Kimberly McGregor, Rachel B. Keller
Published 2023-08-01

Genomic landscape of 891 RET fusions detected across diverse solid tumor types

by Vamsi Parimi, Khaled Tolba, Natalie Danziger, Zheng Kuang, Daokun Sun, Douglas I. Lin, Matthew C. Hiemenz, Alexa B. Schrock, Jeffrey S. Ross, Geoffrey R. Oxnard, Richard S. P. Huang
Published 2023-01-01

Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis

by David P Carbone, David Spigel, Jeffrey S Ross, Karthikeyan Murugesan, Gerald Li, Richard S P Huang, Ryon P Graf, Geoffrey R Oxnard, Alexa Schrock, Liangliang Zhang, Khaled Tolba, Jacob Sands
Published 2023-01-01

Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivol...

by Jie He, David Fabrizio, Jonathan Baden, Parul Doshi, James Pratt, Lee A Albacker, Geoffrey R Oxnard, Gina Fusaro, Natallia Kalinava, Dean C Pavlick, Ericka M Ebot, Hanna Tukachinsky, George Green
Published 2023-11-01

Early circulating tumor DNA dynamics as a pan‐tumor biomarker for long‐term clinical outcome in patients treated with durvalumab and tremelimumab

by Maya Kansara, Neeru Bhardwaj, Subotheni Thavaneswaran, Chang Xu, Jessica K. Lee, Lo‐Bin Chang, Russell W. Madison, Frank Lin, Eugene Hsu, Vipul Kumar Patel, Alexey Aleshin, Geoffrey R. Oxnard, John Simes, Halla Nimeiri, David M. Thomas
Published 2023-02-01

Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations

by Atsuko Ogino, Jihyun Choi, Mika Lin, Margaret K. Wilkens, Antonio Calles, Man Xu, Anika E. Adeni, Emily S. Chambers, Marzia Capelletti, Mohit Butaney, Nathanael S. Gray, Prafulla C. Gokhale, Sangeetha Palakurthi, Paul Kirschmeier, Geoffrey R. Oxnard, Lynette M. Sholl, Pasi A. Jänne
Published 2021-01-01

The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice

by Lincoln D. Nadauld, Charles H. McDonnell, Tomasz M. Beer, Minetta C. Liu, Eric A. Klein, Andrew Hudnut, Richard A. Whittington, Bruce Taylor, Geoffrey R. Oxnard, Jafi Lipson, Margarita Lopatin, Rita Shaknovich, Karen C. Chung, Eric T. Fung, Deborah Schrag, Catherine R. Marinac
Published 2021-07-01

Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC

by Lee S. Schwartzberg, MD, Gerald Li, PhD, Khaled Tolba, MD, Ariel B. Bourla, MD, PhD, Katja Schulze, PhD, Rujuta Gadgil, MS, Alexander Fine, PhD, Katherine T. Lofgren, PhD, Ryon P. Graf, PhD, Geoffrey R. Oxnard, MD, Davey Daniel, MD
Published 2022-09-01

Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors

by Jessica K. Lee, Smruthy Sivakumar, Alexa B. Schrock, Russell Madison, David Fabrizio, Ole Gjoerup, Jeffrey S. Ross, Garrett M. Frampton, Pavel Napalkov, Meagan Montesion, Jennifer L. Schutzman, Xin Ye, Priti S. Hegde, Misako Nagasaka, Geoffrey R. Oxnard, Ethan S. Sokol, Sai-Hong Ignatius Ou, Zhen Shi
Published 2022-12-01

Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer

by Smruthy Sivakumar, Dexter X. Jin, Hanna Tukachinsky, Karthikeyan Murugesan, Kimberly McGregor, Natalie Danziger, Dean Pavlick, Ole Gjoerup, Jeffrey S. Ross, Robert Harmon, Jon Chung, Brennan Decker, Lucas Dennis, Garrett M. Frampton, Luciana Molinero, Steffi Oesterreich, Jeffrey M. Venstrom, Geoffrey R. Oxnard, Priti S. Hegde, Ethan S. Sokol
Published 2022-12-01

Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline EGFR T790M Mutation

by Netta Mäkinen, PhD, Meng Zhou, PhD, Meredith Bemus, BS, Julius Nevin, BS, Anwesha Nag, PhD, Ruthia Chen, BA, Yolonda L. Colson, MD, PhD, Aaron R. Thorner, PhD, Geoffrey R. Oxnard, MD, Matthew Meyerson, MD, PhD, Lynette M. Sholl, MD
Published 2021-04-01

The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung Cancer

by Barbara J. Gitlitz, MD, Silvia Novello, MD, PhD, Tiziana Vavalà, MD, Marisa Bittoni, PhD, Alicia Sable-Hunt, RN, MBA, Dean Pavlick, BS, Robert Hsu, MD, S. Lani Park, PhD, MPH, Ruthia Chen, BA, Matthew Cooke, BA, Amy Moore, PhD, Alexa B. Schrock, PhD, Joan H. Schiller, MD, Bonnie J. Addario, Geoffrey R. Oxnard, MD
Published 2021-07-01

Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors

by Yoshihisa Kobayashi, Geoffrey R. Oxnard, Elizabeth F. Cohen, Navin R. Mahadevan, Joao V. Alessi, Yin P. Hung, Arrien A. Bertram, David E. Heppner, Mauricio F. Ribeiro, Karina P. Sacardo, Rodrigo Saddi, Mariana P. Macedo, Rafael B. Blasco, Jiaqi Li, Kari J. Kurppa, Tom Nguyen, Emma Voligny, Guruprasad Ananda, Roberto Chiarle, Artur Katz, Michael Y. Tolstorukov, Lynette M. Sholl, Pasi A. Jänne
Published 2022-09-01

Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC

by Dong-Wan Kim, MD, PhD, Shirish Gadgeel, MD, Scott N. Gettinger, MD, Gregory J. Riely, MD, PhD, Geoffrey R. Oxnard, MD, Tarek Mekhail, MD, Peter Schmid, MD, PhD, Afshin Dowlati, MD, Rebecca S. Heist, MD, MPH, Antoinette J. Wozniak, MD, Jatinder Singh, PhD, Edward Cha, MD, PhD, Jessica Spahn, PhD, Sai-Hong Ignatius Ou, MD, PhD
Published 2022-08-01

SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping

by Marissa N. Lawrence, BS, Rubii M. Tamen, BA, Pablo Martinez, MD, PhD, Alicia Sable-Hunt, RN, MBA, CCRA, Tony Addario, Pete Barbour, MS, MPM, PMP, Tristan Shaffer, BS, Seyed Ali Hosseini, MD, PhD, Caterina Bertucci, BS, MPA, Lee P. Lim, PhD, Fangxin Hong, PhD, Kesi Michael, BS, George R. Simon, MD, Jonathan W. Riess, MD, PhD, Mark M. Awad, MD, PhD, Geoffrey R. Oxnard, MD
Published 2021-04-01

MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

by Awad, Mark Magdi, Oxnard, Geoffrey Raymond, Jackman, David M, Savukoski, Daniel O., Hall, Dimity, Shivdasani, Priyanka, Heng, Jennifer C., Dahlberg, Suzanne Eleanor, Janne, Pasi Antero, Verma, Suman, Christensen, James, Hammerman, Peter Seth, Sholl, Lynette Marie
Published 2017